Adam S. Asch

Hematology

800 NE 10th St
Oklahoma City, OK 73104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

The role of interim bone marrow assessments in acute myeloid leukemia - A systematic review and meta-analysis.

The role of interim bone marrow assessments in acute myeloid leukemia - A systematic review and meta-analysis.

Journal: Leukemia research

Published: August 02, 2025

Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.

Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia.

Journal: EJHaem

Published: April 02, 2025

Correction: Singh et al. Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models. Cells 2024, 13, 1463.

Correction: Singh et al. Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models. Cells 2024, 13, 1463.

Journal: Cells

Published: January 17, 2025

Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models.

Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models.

Journal: Cells

Published: August 07, 2024

Impact of Primary Disease Site of Involvement by Early-Stage Follicular Lymphoma on Patient Outcomes.

Impact of Primary Disease Site of Involvement by Early-Stage Follicular Lymphoma on Patient Outcomes.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 23, 2024

Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Journal: Blood advances

Published: April 12, 2024

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.

Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.

Journal: British journal of haematology

Published: January 30, 2024

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 13, 2023

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 28, 2023

Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival.

Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival.

Journal: Cancer medicine

Published: June 19, 2023

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 08, 2023

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 20, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026